5 completed. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 2 | Completed 2 |
Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors FT500, Nivolumab, Pembrolizumab - Advanced Solid Tumors, Lymphoma | Phase 1 | Completed | Fate Therapeutics | 37 | 2019-02-15 | 2023-05-01 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies INCAGN02385 - Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer | Phase 1 | Completed | Incyte Biosciences International Sàrl | 22 | 2018-06-18 | 2020-10-30 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors APL-501 - Solid Tumor, Microsatellite Instability | Phase 1 | Completed | Apollomics (Australia) Pty. Ltd. | 30 | 2017-03-27 | 2022-05-09 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers MK-3475, INCB024360 - Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 444 | 2014-07-17 | 2022-02-14 |
Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Stomach Neoplasms (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Lymphoma (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2)
Genomic Instability (5) · Neoplasms (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Neoplasms by Site (4) · Adenocarcinoma (3) · Breast Diseases (3) · Carcinoma (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3)
pembrolizumab (2) · Cyclophosphamide (1) · Interleukin-2 (1) · Nivolumab (1) · aldesleukin (1) · atezolizumab (1) · bintrafusp alfa protein, human (1) · epacadostat (1) · fludarabine (1)
Apollomics (Australia) Pty. Ltd. (1) · Fate Therapeutics (1) · Incyte Biosciences International Sàrl (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1)
United States (4) · Australia (1)
John Janik, MD (1) · Marietta Franco (1) · Mark Jones, MD (1) · Van K Morris, MD (1)